First Department of Surgery, Laikon General Hospital, Athens, Greece.
1st Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece.
In Vivo. 2020 Nov-Dec;34(6):3127-3136. doi: 10.21873/invivo.12147.
BACKGROUND/AIM: Thyroid dysfunction, both hypo- and hyperthyroidism, has been associated with cardiovascular disease. The aim of this study was to evaluate the association between thyroid dysfunction and atherosclerosis measured mostly by carotid intima-media thickness, as well as discuss whether L-T4 replacement is able to reverse or slow down the progression of atherosclerosis. MATERIALS AND METHODS: The review was conducted according the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We performed on PubMed a literature search from May 2004 to January 2020, using the search terms 'subclinical hypothyroidism' or 'thyroid disorders' and 'carotid artery', 'carotid intima-media thickness (IMT)', 'levothyroxine', and 'atherosclerosis'. RESULTS: Twenty-six studies were eligible and included in the analysis. Overall, the studies encompassed a total of 36.434 patients included in this review. Most studies indicated a proportional correlation between IMT and thyroid dysfunction. Levothyroxine (L-T4) replacement led to significant decrease of IMT after 1 year in most studies. CONCLUSION: Most studies have concluded that thyroid dysfunction is associated with arterial wall remodeling and, thus, with increased cardiovascular risk. However, the exact mechanistic background of pathological structural changes in the arterial wall is still unsettled. Large randomized controlled studies are required to definitively address the extent to which T4 replacement therapy might benefit patients with subclinical thyroid disorders.
背景/目的:甲状腺功能减退症和甲状腺功能亢进症均与心血管疾病相关。本研究旨在评估甲状腺功能障碍与动脉粥样硬化的相关性,该研究主要通过测量颈动脉内膜中层厚度来评估,同时还讨论了左甲状腺素(L-T4)替代治疗是否能够逆转或减缓动脉粥样硬化的进展。
材料和方法:本综述按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行。我们在 PubMed 上进行了文献检索,检索时间从 2004 年 5 月到 2020 年 1 月,使用的检索词包括“亚临床甲状腺功能减退症”或“甲状腺疾病”以及“颈动脉”、“颈动脉内膜中层厚度(IMT)”、“左甲状腺素”和“动脉粥样硬化”。
结果:共有 26 项研究符合条件并纳入分析。总的来说,这些研究共纳入了 36434 名患者。大多数研究表明,IMT 与甲状腺功能障碍之间存在比例相关性。在大多数研究中,左甲状腺素(L-T4)替代治疗在 1 年后可显著降低 IMT。
结论:大多数研究表明甲状腺功能障碍与动脉壁重塑有关,因此与心血管风险增加有关。然而,动脉壁病理性结构变化的确切机制背景仍未确定。需要进行大规模的随机对照研究,以明确 T4 替代治疗在多大程度上可能使亚临床甲状腺疾病患者受益。
Nutr Metab Cardiovasc Dis. 2015-12
J Clin Endocrinol Metab. 2018-8-1
Arch Endocrinol Metab. 2019-2
Rom J Intern Med. 2022-3-1
Front Endocrinol (Lausanne). 2025-2-17
SAGE Open Med. 2024-12-23
Rev Cardiovasc Med. 2022-4-11
Diabetes Metab Syndr Obes. 2023-10-12
Front Cardiovasc Med. 2022-11-29
Front Endocrinol (Lausanne). 2020-1-9
Turk J Med Sci. 2019-10-24
Eur Rev Med Pharmacol Sci. 2019-3
Endocr Connect. 2018-10-1
J Clin Endocrinol Metab. 2018-8-1
PLoS One. 2017-7-27
J Clin Res Pediatr Endocrinol. 2017-6-1